Last reviewed · How we verify
Fluorouracil implant
Fluorouracil implant delivers the chemotherapy agent 5-fluorouracil directly to tumor tissue to inhibit thymidylate synthase and disrupt DNA synthesis in cancer cells.
Fluorouracil implant delivers the chemotherapy agent 5-fluorouracil directly to tumor tissue to inhibit thymidylate synthase and disrupt DNA synthesis in cancer cells. Used for Colorectal cancer, Breast cancer.
At a glance
| Generic name | Fluorouracil implant |
|---|---|
| Also known as | Sinofuan |
| Sponsor | Austrian Breast & Colorectal Cancer Study Group |
| Drug class | Antimetabolite chemotherapy agent |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Fluorouracil (5-FU) is a pyrimidine analog that inhibits thymidylate synthase, blocking dTMP synthesis and disrupting DNA replication in rapidly dividing cells. The implant formulation provides local or regional drug delivery to maximize tumor exposure while potentially reducing systemic toxicity. This approach is particularly relevant for colorectal and breast cancers where regional or local delivery can improve therapeutic efficacy.
Approved indications
- Colorectal cancer
- Breast cancer
Common side effects
- Myelosuppression
- Gastrointestinal toxicity
- Hand-foot syndrome
- Mucositis
- Local tissue reaction at implant site
Key clinical trials
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- Optimizing Graft Selection in Glaucoma Surgery: A Comparative Study of Sclera, Pericardium, and Corneal Tissue (NA)
- Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer (PHASE1)
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer (EARLY_PHASE1)
- FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma (PHASE2)
- Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver (PHASE2)
- Biliary Drainage Plus HAIC in Locally Advanced pCCA (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluorouracil implant CI brief — competitive landscape report
- Fluorouracil implant updates RSS · CI watch RSS
- Austrian Breast & Colorectal Cancer Study Group portfolio CI